These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 37111304)
1. Technologies for Direct Detection of Covalent Protein-Drug Adducts. Mons E; Kim RQ; Mulder MPC Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111304 [TBL] [Abstract][Full Text] [Related]
2. [Advances in applications of activity-based chemical probes in the characterization of amino acid reactivities]. Li J; Wang G; Ye M; Qin H Se Pu; 2023 Jan; 41(1):14-23. PubMed ID: 36633073 [TBL] [Abstract][Full Text] [Related]
3. Separation and detection methods for covalent drug-protein adducts. Zhou S J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Nov; 797(1-2):63-90. PubMed ID: 14630144 [TBL] [Abstract][Full Text] [Related]
4. Recent progress in covalent warheads for in vivo targeting of endogenous proteins. Shindo N; Ojida A Bioorg Med Chem; 2021 Oct; 47():116386. PubMed ID: 34509863 [TBL] [Abstract][Full Text] [Related]
5. Electrophilic warheads in covalent drug discovery: an overview. Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005 [TBL] [Abstract][Full Text] [Related]
6. Drug discovery considerations in the development of covalent inhibitors. Mah R; Thomas JR; Shafer CM Bioorg Med Chem Lett; 2014 Jan; 24(1):33-9. PubMed ID: 24314671 [TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. Zhang T; Hatcher JM; Teng M; Gray NS; Kostic M Cell Chem Biol; 2019 Nov; 26(11):1486-1500. PubMed ID: 31631011 [TBL] [Abstract][Full Text] [Related]
9. Advances in MS Based Strategies for Probing Ligand-Target Interactions: Focus on Soft Ionization Mass Spectrometric Techniques. Chen G; Fan M; Liu Y; Sun B; Liu M; Wu J; Li N; Guo M Front Chem; 2019; 7():703. PubMed ID: 31709232 [TBL] [Abstract][Full Text] [Related]
10. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins. Yang Y; Shu YZ; Humphreys WG Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335 [TBL] [Abstract][Full Text] [Related]
11. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Lu H; Tonge PJ Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820 [TBL] [Abstract][Full Text] [Related]
12. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Zhou S; Chan E; Duan W; Huang M; Chen YZ Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500 [TBL] [Abstract][Full Text] [Related]
13. Covalent Docking in Drug Discovery: Scope and Limitations. Scarpino A; Ferenczy GG; Keserű GM Curr Pharm Des; 2020; 26(44):5684-5699. PubMed ID: 33155894 [TBL] [Abstract][Full Text] [Related]
14. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Schwartz PA; Kuzmic P; Solowiej J; Bergqvist S; Bolanos B; Almaden C; Nagata A; Ryan K; Feng J; Dalvie D; Kath JC; Xu M; Wani R; Murray BW Proc Natl Acad Sci U S A; 2014 Jan; 111(1):173-8. PubMed ID: 24347635 [TBL] [Abstract][Full Text] [Related]
15. Reactive-cysteine profiling for drug discovery. Maurais AJ; Weerapana E Curr Opin Chem Biol; 2019 Jun; 50():29-36. PubMed ID: 30897495 [TBL] [Abstract][Full Text] [Related]
16. A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations. Mons E; Roet S; Kim RQ; Mulder MPC Curr Protoc; 2022 Jun; 2(6):e419. PubMed ID: 35671150 [TBL] [Abstract][Full Text] [Related]